Treatment of Infantile Hemangiomas with Sirolimus in a Patient with PHACE Syndrome
Version of Record online: 15 JAN 2013
© 2013 Wiley Periodicals, Inc.
Volume 30, Issue 6, pages e194–e197, November/December 2013
How to Cite
Kaylani, S., Theos, A. J. and Pressey, J. G. (2013), Treatment of Infantile Hemangiomas with Sirolimus in a Patient with PHACE Syndrome. Pediatric Dermatology, 30: e194–e197. doi: 10.1111/pde.12023
- Issue online: 13 NOV 2013
- Version of Record online: 15 JAN 2013
Infantile hemangiomas (IHs) are common benign tumors of childhood. IHs often regress satisfactorily without intervention, but a subset of IHs may lead to functional or cosmetic morbidity necessitating therapy. PHACE syndrome is characterized by a variety of neurocutaneous and vascular anomalies that typically include segmental hemangiomas. We present an infant with PHACE syndrome and segmental IH that failed conventional first-line therapies. Treatment with sirolimus provided benefit with regression of the cutaneous IH. As an inhibitor of the mammalian target of rapamycin (mTOR) pathway, the effective use of sirolimus may shed light on the emerging role of mTOR signaling in the development and pathogenesis of IHs.